Clinical and biochemical characteristics of patients with somatic HRAS -mutant pheochromocytoma and paraganglioma
Authors' conclusion
Patients with HRAS-mutant PPGL have higher plasma metanephrine levels and a higher risk of IHI and ICU transfer, which therefore requires personalized perioperative managements.
Study context
- Population
- Chinese patients with PPGL
- Participants
- 717 patients
- Exposure
- HRAS-mutant vs non-HRAS PPGL
- HRAS-mutant PPGLn = 111
- Outcome
- Frequency of HRAS PVs
Main finding
As reported in the abstract
HRAS-mutant PPGL
15.5%
111
Observational data: associations, not effects.
Further findings
HRAS-mutant vs PPGL with pathogenic variants (PVs) in other kinase-pathway genes
- Despite similar tumor size, significantly higher plasma metanephrine levels and higher incidence of CAS and intraoperative hemodynamic instability (IHI) with HRAS-mutant PPGL
Tumor catecholamine content
- High catecholamine content in HRAS-mutant PPGL associated with high levels of tyrosine hydroxylase and phenylethanolamine N-methyltransferase, independent of tumor location
Safety
Perioperative events
- Increased incidence of IHI and intensive care unit (ICU) transfer right after surgery with HRAS-mutant vs non-HRAS PPGL
Original publication
Clinical and biochemical characteristics of patients with somatic HRAS -mutant pheochromocytoma and paraganglioma. Eur J Endocrinol. Published 9 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →